Lung cancer is the most common malignancy worldwide. Approximately 1.2 million people are diagnosed with lung cancer annually (accounting for 12.3% of all cancers); the second most common malignancy is breast cancer (10.4%), followed by colorectal cancer (9.4%). As lung cancer almost invariably has a poor prognosis, it is the largest single cause of death from cancer in the world, with a mortality of 1.1 million annually ([Stewart and Kleihues, 2003](#bib42){ref-type="other"}). Only 15% of lung cancer patients have a disease that is confined to the lung and are candidates for surgical resection; most patients with this disease have distant metastases or pleural effusion at the time of their initial diagnosis. These patients can be treated with systemic chemotherapy, but the efficacy of currently available anticancer agents is limited and patients with advanced diseases rarely live long.

As the development of new anticancer agents and chemotherapeutic regimens is both time and money consuming, clinical trials need to be as efficient as possible. One effort in this direction has been the adoption of global clinical trials for new agents that involve trial centres on more than one continent; this strategy enables adequate sample sizes to be obtained in a relatively short-time period and eliminates the need for redundant clinical trials with similar objectives conducted in different countries. However, whether the results of clinical trials performed in one population can be fully extrapolated to other populations remains questionable because of potential differences in trial designs, study-specific criteria, patient demographics, frequency of monitoring, and population-related pharmacokinetics, pharmacodynamics and pharmacogenomics. Recently, these genetic and physiologic factors influencing cancer chemotherapy have been increasingly examined and reported.

Clinical observations of toxicity during cytotoxic chemotherapy
===============================================================

A comparison of phase III trials for the same drug combinations against non-small cell lung cancer conducted in different countries shows a great diversity in toxicity ([Sekine *et al*, 2006](#bib38){ref-type="other"}). Among trials studying the combination of carboplatin and paclitaxel, the dose of carboplatin was fixed in all the trials, but the dose of paclitaxel was 200 mg m^−2^ in Japanese and European trials and 225 mg m^−2^ in American trials. Grades 3--4 neutropenia was noted in 88% of the patients in the Japanese trial, 15--51% of the patients in the European trials, and 6--65% of the patients in the American trials. Meanwhile, grades 3--4 febrile neutropenia was encountered in 16% of the patients in the Japanese trial, 0--9% of the patients in the European trials, and 2--4% of the patients in the American trials ([Table 1](#tbl1){ref-type="table"}). For combinations of cisplatin and docetaxel ([Table 1](#tbl1){ref-type="table"}) and cisplatin and vinorelbine ([Table 2](#tbl2){ref-type="table"}), the incidences of grades 3--4 neutropenia and febrile neutropenia were almost the same between phase III trials performed in different areas, but the doses of docetaxel and vinorelbine in the Japanese trials were lower than those in the European and American trials. Thus, neutropenia in patients receiving a combination of platinum and antimicrotubule agents may be more severe in Japanese than in Europeans and Americans. A higher frequency of grades 3--4 neutropenia in Japanese patients than in American patients was associated with combinations of cisplatin and irinotecan (65 *vs* 32%, *P*\<0.001) and cisplatin and etoposide (92 *vs* 66%, *P*\<0.001) for the treatment of extensive small-cell lung cancer ([Lara *et al*, 2007](#bib21){ref-type="other"}).

How can this ethnic difference in the severity of neutropenia be explained? One possibility is that the physiological capacity of the white blood cell production and maturation may vary among different ethnic populations. An asymptomatic reduction in neutrophils (benign neutropenia) is more commonly observed in individuals of African descent than in Caucasians, and no data on this phenomenon are available for Asians ([Hsieh *et al*, 2007](#bib16){ref-type="other"}). The mechanisms are unclear, but a lower bone marrow reserve, an intrinsic marrow difference, an abnormal cytokine response, or any combination of these factors have been suggested ([Hsieh *et al*, 2007](#bib16){ref-type="other"}). The lower neutrophil counts were associated with higher levels of IL-8 and granulocyte colony-stimulating factor in African volunteers. Thus, these cytokines are considered to compensate for the relatively low neutrophil counts in this population ([Mayr *et al*, 2007](#bib27){ref-type="other"}). A recent report showed that ethnicity-related low neutrophil counts were associated with neutrophil elastase (ELA2) polymorphisms (C-199A), but not with serum cytokine levels ([Grann *et al*, 2007](#bib13){ref-type="other"}).

Ethnic differences in drug metabolising enzymes
===============================================

An explanation for the ethnic differences in haematological toxicity may be the varying activities of drug-metabolising enzymes and transporters that are mainly associated with polymorphisms in the promoter and coding regions of these enzymes ([Fujita and Sasaki, 2007](#bib9){ref-type="other"}). The haematological toxicity of docetaxel monotherapy was associated with the clearance of this agent in Asian patients, a phenomenon that can be largely explained by CYP3A4 activity ([Yamamoto *et al*, 2000](#bib47){ref-type="other"}). A study conducted in the Netherlands showed that docetaxel clearance was associated with the homozygous C1236T polymorphism in the ABCB1 (p-glycoprotein) gene (ABCB1\*8) but was not associated with any CYP3A4 gene polymorphisms ([Bosch *et al*, 2006](#bib3){ref-type="other"}). In contrast, docetaxel pharmacokinetics were not associated with the percent decrease in neutrophil counts nor with any polymorphisms in the CYP3A4 and ABCB1 genes in American patients ([Lewis *et al*, 2007](#bib23){ref-type="other"}). Another example of ethnic differences in drug-metabolising enzymes is the association between polymorphisms in genes involved in irinotecan metabolism and irinotecan-induced neutropenia. Among the patients who received irinotecan with or without another anticancer agent, grade 4 neutropenia was noted in 40--57% of the patients with UDP-glucuronosyltransferase (UGT) 1A1^\*^28 (a polymorphism in the promoter region of the UGT1A1 gene) homozygosity, whereas neutropenia was only observed in 15% or less of the patients with wild-type alleles. This association was consistent in both Asian and Caucasian patients, although the frequency of homozygosity was about 10% in Caucasians and much lower in Asians. The UGT1A1\*6 allele is another polymorphism at exon 1 that is associated with defective glucuronidating function and is found almost exclusively in Asian individuals with a frequency as high as 20% ([Fujita and Sasaki, 2007](#bib9){ref-type="other"}). UGT1A1\*6 is significantly linked to polymorphisms of UGT1A7 and UGT1A9. A haplotype including UGT1A1\*6 and UGT1A7\*3, noted in as many as 15% of Japanese patients, and UGT1A1\*6 homozygosity, noted in 7% of Korean patients, were significantly associated with decreased glucuronosyltransferase activity for SN-38 and severe neutropenia ([Han *et al*, 2006](#bib14){ref-type="other"}; [Fujita *et al*, 2007](#bib8){ref-type="other"}). In 177 Japanese patients treated with irinotecan-including chemotherapy, a homozygous or double heterozygous genotype for UGT1A1^\*^6 and UGT1A1^\*^28 (^\*^6/^\*^6, ^\*^28/^\*^28 or ^\*^6/^\*^28) was significantly associated with severe neutropenia ([Minami *et al*, 2007](#bib28){ref-type="other"}). In addition, patients with a homozygous C3435T polymorphism in the ABCB1 gene are four-fold more likely to develop grade 3 diarrhoea when treated with a combination of cisplatin and irinotecan ([Lara *et al*, 2007](#bib21){ref-type="other"}).

Data on associations between polymorphisms in genes coding drug-metabolising enzymes and therapeutic efficacy remain scarce. A recent prospective study in 250 patients with metastatic colorectal cancer showed a significantly higher response rate (67 *vs* 40%) and a nonsignificant survival advantage (hazard ratio (HR): 0.81; 95% confidence interval (CI): 0.45--1.44) in patients homozygous for UGT1A1^\*^28, compared with those with wild-type alleles; these outcomes were associated with a higher exposure to SN-38 ([Toffoli *et al*, 2006](#bib45){ref-type="other"}). In a study of 81 NSCLC patients, those who were homozygous for UGT1A1^\*^6 had a lower response rate (0 *vs* 50%, *P*=0.038) and a poorer MST (7.6 *vs* 17.7 months, *P*=0.017) as well as greater toxicities than the other patients ([Han *et al*, 2006](#bib14){ref-type="other"}). The most plausible explanation for the negative effects of UGT1A1^\*^6 on treatment outcome may be that the dose intensity or cycle number might have been reduced in patients with UGT1A1^\*^6 because of polymorphism-associated toxicities ([Fujita and Sasaki, 2007](#bib9){ref-type="other"}).

These pharmacogenetic analyses have been rather preliminary. Data on genotyping, pharmacokinetics, and pharmacodynamics collected from a large number of patients with different ethnic backgrounds are needed to demonstrate the cause of ethnic differences in chemotherapy-associated toxicity.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors
=======================================================================

Epidermal growth factor receptor (EGFR), a cell membrane receptor with tyrosine kinase activity, is expressed in most patients with NSCLC and plays a role in cellular proliferation, inhibition of apoptosis, angiogenesis, metastatic potential, and chemoresistance. Small-molecule inhibitors of EGFR, such as gefitinib and erlotinib, have shown antitumor activity and have alleviated symptoms in NSCLC patients who were previously treated with standard chemotherapy. Two randomized phase II studies, IDEAL (Iressa Dose Evaluation in Advanced Lung Cancer)-1 (involving 210 patients and conducted in Europe, Australia, South Africa, and Japan) and IDEAL-2 (involving 216 patients and conducted in the USA), have evaluated the efficacy of gefitinib at a dose of either 250 mg daily or 500 mg daily in patients with advanced NSCLC in whom earlier platinum-based chemotherapy had failed. No difference in the response rates between the doses was noted, but an increased response rate was recorded for never smokers, women, and those with an adenocarcinoma histology, compared with patients who did not have these characteristics. In addition, the response rate was 28% in Japanese patients but only 9--12% in patients of other ethnicities ([Fukuoka *et al*, 2003](#bib10){ref-type="other"}; [Kris *et al*, 2003](#bib20){ref-type="other"}). A randomized phase III trial, ISEL (Iressa Survival Evaluation in Lung Cancer), of gefitinib *vs* a placebo in 1692 NSCLC patients who had been previously treated with one or two chemotherapeutic regimens failed to show any survival benefit of gefitinib; in the overall population, the median survival times (MSTs) in the gefitinib and placebo arms were 5.6 and 5.1 months, respectively (HR: 0.89; 95% CI: 0.78--1.03). A subgroup analysis, however, showed that the MST was longer in Asian patients receiving gefitinib than in those receiving the placebo (MST: 9.5 *vs* 5.5 months; HR: 0.66; 95% CI: 0.48--0.91). Similar results were seen for never smokers: patients receiving gefitinib survived longer than those receiving the placebo (MST: 8.9 *vs* 6.1 months; HR: 0.67, 95% CI: 0.49--0.91) ([Thatcher *et al*, 2005](#bib44){ref-type="other"}).

A similar association between objective responses and ethnicity was observed in studies on erlotinib monotherapy for previously treated advanced NSCLC. In an American phase II trial of this agent in 57 advanced NSCLC patients with disease progression or relapse after platinum-based chemotherapy, the response rate was 12% and the MST was 8.4 months ([Perez-Soler *et al*, 2004](#bib32){ref-type="other"}). In contrast, the combined data of two Japanese phase II trials of erlotinib in similar patient populations showed objective responses in 30 of 106 (28%) patients and an MST of 13.8 months. Among the responders, significantly higher proportions of females (50%) than males (17%) (*P*=0.0009) and of never smokers (51%) than smokers (14%) were observed (*P*\<0.0001) ([Tamura *et al*, 2007](#bib43){ref-type="other"}). A phase III trial of erlotinib or a placebo in 731 NSCLC patients previously treated with one or two chemotherapy regimens showed that the response rate in Asian patients was higher than that in patients of other ethnicities (28 *vs* 10%, *P*=0.02) ([Shepherd *et al*, 2005](#bib39){ref-type="other"}).

These results of phases II and III trials consistently suggest that EGFR tyrosine kinase inhibitors may be more effective in Asian patients than in patients of other ethnicities.

In April 2004, the activating mutations of the EGFR gene were identified in NSCLC specimens, and cancers with these mutations were reported to be highly sensitive to gefitinib. The populations with higher responses to gefitinib (females, non-smokers and patients with an adenocarcinoma histology) also have higher incidences of EGFR mutations ([Kosaka *et al*, 2004](#bib18){ref-type="other"}; [Pao *et al*, 2004](#bib31){ref-type="other"}; [Shigematsu *et al*, 2005](#bib40){ref-type="other"}). The incidence of EGFR mutations in surgically resected tissue samples is summarised in [Table 3](#tbl3){ref-type="table"} ([Kosaka *et al*, 2004](#bib18){ref-type="other"}; [Pao *et al*, 2004](#bib31){ref-type="other"}; [Marchetti *et al*, 2005](#bib26){ref-type="other"}; [Qin *et al*, 2005](#bib34){ref-type="other"}; [Shigematsu *et al*, 2005](#bib40){ref-type="other"}; [Soung *et al*, 2005](#bib41){ref-type="other"}; [Tokumo *et al*, 2005](#bib46){ref-type="other"}; [Yang *et al*, 2005](#bib48){ref-type="other"}; [Sasaki *et al*, 2006](#bib36){ref-type="other"}). The incidence varies from one report to another, but EGFR mutations tend to be more common among patients with an adenocarcinoma histology and among non-smokers. Among Asian patients, the average incidences of EGFR mutations were 31% overall, 47% among patients with adenocarcinoma, and 56% among non-smokers; among other ethnic populations, however, the average incidences were 7--8% overall, 13--15% among patients with adenocarcinoma, and 34--35% among non-smokers ([Table 3](#tbl3){ref-type="table"}). Thus, the percentage of responders to gefitinib or erlotinib almost paralleled the percentage of patients with EGFR mutations.

The mechanism responsible for the high frequency of EGFR mutations in Asian patients is a subject of great interest, and polymorphisms in the regulatory sequence of the EGFR gene have been vigorously investigated. The CA simple sequence repeat 1 (CA-SSR1), a highly polymorphic locus containing 14--21 CA dinucleotide repeats, is located at the 5′ end of intron 1 of the EGFR gene. Studies of CA-SSR1 repeat length and EGFR expression in breast cancer tissues have shown a constant decline in EGFR expression with increasing repeat length ([Buerger *et al*, 2000](#bib4){ref-type="other"}, [2004](#bib5){ref-type="other"}). In addition, a shorter repeat length was associated with an elevated risk of lung cancer ([Zhang *et al*, 2007](#bib49){ref-type="other"}) and poor survival in NSCLC patients ([Dubey *et al*, 2006](#bib6){ref-type="other"}). The CA-SSR1 repeat length distribution varies according to ethnicity, with Asians tending to have longer repeats than Americans ([Liu *et al*, 2003](#bib24){ref-type="other"}). Two single-nucleotide polymorphisms in the promoter region of the EGFR gene (−219G/T and −191C/A) were also associated with promoter activity and EGFR expression ([Liu *et al*, 2005](#bib25){ref-type="other"}), and their polymorphic types (associated with low EGFR expression) were more common among Asians than among other ethnicities ([Nomura *et al*, 2007](#bib29){ref-type="other"}). These observations suggest that many Asians have polymorphic types that lead to a decreased intrinsic production of EGFR protein. If a certain critical level of EGFR is required to drive the cell toward a malignant phenotype, another mechanism including activating mutations of EGFR and/or the autonomous activation of downstream signalling may be required for the development of lung cancer among Asians ([Nomura *et al*, 2007](#bib29){ref-type="other"}).

Interstitial lung disease associated with gefitinib and erlotinib
=================================================================

The frequencies of grades 3--4 common toxicities after the administration of gefitinib, including diarrhoea, skin rash, and elevated liver transaminase levels, have been similar among study populations, but the incidence of severe interstitial lung disease (ILD) associated with the administration of gefitinib differs between patients in Japan and those in other countries. In the IDEAL studies, two Japanese patients developed grades 3--4 ILD (2%), whereas no patients outside of Japan experienced ILD ([Fukuoka *et al*, 2003](#bib10){ref-type="other"}; [Kris *et al*, 2003](#bib20){ref-type="other"}). A retrospective study of 1976 consecutive patients treated with gefitinib at 84 institutions showed that the incidence of ILD was 3.5% and the mortality rate was 1.6%. Several risk factors for the development of gefitinib-induced ILD were identified in the Japanese population: a history of pulmonary fibrosis, a history of smoking, a poor performance status, and a male sex ([Ando *et al*, 2006](#bib1){ref-type="other"}). A similar incidence of ILD (4.6%) was also noted in association with erlotinib chemotherapy in Japanese phase II trials ([Tamura *et al*, 2007](#bib43){ref-type="other"}).

The association between ILD and anticancer treatment is a major topic in Japan because (1) the diagnosis of ILD can be difficult and a consensus among physicians is sometimes not reached, (2) the risk factors for ILD have not been fully established, 3) an effective treatment for ILD has not been established and the condition is often fatal, and (4) the low frequency of this complication makes it difficult to conduct pertinent clinical trials. Gefitinib-induced ILD seems to be more common among Japanese patients than among other patients, but the reasons for this ethnic difference are totally unknown.

Conclusion
==========

The findings discussed here suggest that considerable variations in the toxicity and efficacy of anticancer agents may exist among patients of different ethnicities. Although research into these differences has just begun, these studies suggest that possible pharmacogenomic and tumour genetic differences associated with individual responses to anticancer agents should be carefully considered when conducting global clinical trials.
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###### 

Toxicity associated with a combination of platinum and taxane

                                                  **Chemotherapy dose**                    **Grades 3--4 toxicity (%)**               
  ----------------------------------------------- ----------------------- ---------------- ------------------------------ ----- ----- -----------------------------------------------------
  *A combination of carboplatin and paclitaxel*                                                                                       
   Japan                                          6 (AUC)                 200 (mg m^−2^)   145                            88    16    [Ohe *et al* (2007)](#bib30){ref-type="other"}
   Greece                                         6 (AUC)                 200 (mg m^−2^)   252                            15    0     [Kosmidis *et al* (2002)](#bib19){ref-type="other"}
   EU                                             6 (AUC)                 200 (mg m^−2^)   309                            51    4     [Rosell *et al* (2002)](#bib35){ref-type="other"}
   ECOG                                           6 (AUC)                 225 (mg m^−2^)   290                            63    4     [Schiller *et al* (2002)](#bib37){ref-type="other"}
   SWOG                                           6 (AUC)                 225 (mg m^−2^)   206                            57    2     [Kelly *et al* (2001)](#bib17){ref-type="other"}
   SWOG                                           6 (AUC)                 225 (mg m^−2^)   182                            ---   3     [Gandara *et al* (2004)](#bib11){ref-type="other"}
   USA                                            6 (AUC)                 225 (mg m^−2^)   190                            65    ---   [Belani *et al* (2005)](#bib2){ref-type="other"}
   USA                                            6 (AUC)                 225 (mg m^−2^)   345                            6     ---   [Herbst *et al* (2004)](#bib15){ref-type="other"}
                                                                                                                                       
  *A combination of cisplatin and docetaxel*                                                                                          
   Japan                                          80 (mg m^−2^)           60 (mg m^−2^)    151                            74    2     [Ohe *et al* (2007)](#bib30){ref-type="other"}
   ECOG                                           75 (mg m^−2^)           75 (mg m^−2^)    289                            69    11    [Schiller *et al* (2002)](#bib37){ref-type="other"}
   USA                                            75 (mg m^−2^)           75 (mg m^−2^)    408                            75    5     [Fossella *et al* (2003)](#bib7){ref-type="other"}

NP, neutropenia; FNP, febrile neutropenia.

###### 

Toxicity associated with a combination of cisplatin and vinorelbine

           **Chemotherapy dose (mg m**^−**2**^)                    **Grades 3--4 toxicity (%)**             
  -------- -------------------------------------- ---------------- ------------------------------ ---- ---- ---------------------------------------------------------
  Japan    80 (day 1)                             25 (days 1, 8)   145                            88   18   [Ohe *et al* (2007)](#bib30){ref-type="other"}
  Greece   80 (day 8)                             30 (days 1, 8)   204                            37   11   [Georgoulias *et al* (2005)](#bib12){ref-type="other"}
  France   100 (day 1)                            30 (weekly)      156                            83   22   [Pujol *et al* (2005)](#bib33){ref-type="other"}
  EU       120 (day 1)                            30 (weekly)      206                            79   4    [Le Chevalier *et al* (1994)](#bib22){ref-type="other"}
  SWOG     100 (day 1)                            25 (weekly)      202                            76   1    [Kelly *et al* (2001)](#bib17){ref-type="other"}
  USA      100 (day 1)                            25 (weekly)      404                            79   5    [Fossella *et al* (2003)](#bib7){ref-type="other"}

NP, neutropenia; FNP, febrile neutropenia.

###### 

Incidence of EGFR mutations in surgically resected specimens

                                **All cases**   **Adenocarcinoma**   **Non-smokers**                       
  ----------------- ----------- --------------- -------------------- ----------------- ---------- -------- ----------
  *Western areas*                                                                                          
   Shigematsu       USA         80              11 (14)              44                11 (25)    26       7 (27)
   Pao              USA         96              11 (11)              72                11 (15)    15       7 (47)
   Yang             USA         219             26 (12)              164               25 (15)    34       12 (35)
   Marchetti        Italy       860             39 (5)               375               39 (10)    103^a^   23 (22)
                                                                                                            
                    Subtotal    1255            87 (7)               655               86 (13)    75       26 (35)
                                                                                                            
  *Asian areas*                                                                                            
   Shigematsu       Japan       263             71 (27)              154               67 (44)    78       47 (60)
   Kosaka           Japan       277             111 (40)             224               110 (49)   112^a^   76 (68)
   Tokumo           Japan       120             38 (32)              82                37 (45)    36       25 (69)
   Sasaki           Japan       95              35 (37)              71                32 (45)    36       25 (69)
   Shigematsu       Taiwan      93              32 (34)              55                31 (56)    55       27 (49)
   Qin              China       41              10 (24)              17                7 (41)     21       6 (29)
   Soung            Korea       153             30 (20)              69                26 (38)    54       25 (46)
   Shigematsu       Others      361             107 (30)             214               102 (48)   135      76 (56)
                                                                                                            
                    Subtotal    1403            434 (31)             886               412 (47)   415      231 (56)
                                                                                                            
  *Other areas*                                                                                            
   Shigematsu       Australia   83              6 (7)                36                5 (14)     7        4 (57)
   Shigematsu       Others      158             13 (8)               75                12 (16)    31       9 (29)
                                                                                                            
                    Subtotal    241             19 (8)               111               17 (15)    38       13 (34)
                                                                                                            
                    Toatl       2899            540 (19)             1652              515 (31)   528      270 (51)

Including only patients with adenocarcinoma histology.
